"Preventing or Treating Relapse After BMT for AML, MDS, or CML
''This phase I/II trial has two arms: (1) prophylactic T-cell therapy for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML) patients with high risk of relapse after BMT, and (2) treatment with T cells for AML/MDS/ CML patients with either minimal residual disease or full hematologic relapse after BMT."
Extrait de Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments